The legal challenge centers on claims that Embecta violated the Securities Exchange Act of 1934 by providing false or misleading information to shareholders. According to the complaint, the company issued fiscal guidance for the second quarter and the full year of 2026 despite internal knowledge that market headwinds—specifically within the pen needle sector—would jeopardize those projections. When the reality of these market pressures surfaced, the resulting stock decline inflicted financial damages upon investors.

Schall, Brown & Schwartz LLP is currently seeking lead plaintiffs for the action. While the class has not yet been formally certified, shareholders who suffered losses are encouraged to evaluate their legal standing. Interested parties can contact attorneys Brian Schall or David Schwartz in Los Angeles for a case review. Participation in the lawsuit does not require an appointment as lead plaintiff, and those who choose not to act may remain absent class members until the court grants certification.